Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for BAYRY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for BAYRY and 80,000+ other tickers.
See exactly how BAYRY's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BAYRY and 80,000+ other tickers.
Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies…
Bayer (OTCPK:BAYZF) remains a long-term Buy, with the stock still undervalued despite ongoing litigation and high debt levels. Litigation risks are easing, with a major Supreme Court win and a key settlement decision expected soon, potentially improving free cash flow. Pharmaceuticals face a patent cliff, but strong growth from Nubeqa, Kerendia, and upcoming launches like asundexian and Beyonttra support future earnings.
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that one late-breaking presentation along with five posters across its cardiovascular programs will be featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Phoenix, Arizona, from October 9-12, 2026. Key Facts A post-hoc analysis from the Phase III REVEAL study, which evaluated the investigational PET radiotracer I 124 evuzamitide for the sensitivity and specificity of cardiac amyloidosis based o.
BAYRY's Kerendia label expansion moves forward as FDA accepts an application for CKD patients without diabetes.
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced a partnership with actress and menopause advocate Melissa Joan Hart to increase awareness about Lynkuet® (elinzanetant) 60mg capsules, Bayer's FDA-approved, hormone-free prescription treatment for moderate to severe hot flashes due to menopause.1 Through the partnership, Hart will share her personal experience with moderate to severe hot flashes due to menopause to help women recognize their symptoms and to encourage more proactive treatmen.
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted the company's supplemental New Drug Application (sNDA) for KERENDIA® (finerenone), which is being investigated for the treatment of adults with chronic kidney disease (CKD) without diabetes who are receiving background standard of care. Key Facts The sNDA was supported by results from the Phase III FIND-CKD trial investigating KERENDIA in adults with CKD without diabete.